Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Sarah K Cimino"'
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Colorectal cancer results in the deaths of hundreds of thousands of patients worldwide each year, with incidence expected to rise over the next two decades. In the metastatic setting, cytotoxic therapy options remain limited, which is reflected in th
Externí odkaz:
https://doaj.org/article/21ed1bae8eb840abb7dbee940bfbb246
Publikováno v:
Clinical Colorectal Cancer. 21:272-275
Autor:
A. Bapsi Chakravarthy, Sarah K Cimino, Cathy Eng, Alexander T. Hawkins, Christina E. Bailey, Timothy M. Geiger, Kristen K. Ciombor, M. Benjamin Hopkins
Publikováno v:
Expert Opinion on Drug Safety. 20:889-902
Introduction: Anal cancer is a rare malignancy, but incidence rates are rising. Primary chemoradiation is the standard of care for early disease with surgery reserved for salvage. Despite success in terms of survival, patients suffer significant morb
Autor:
Jill N Modi, Sarah K Cimino
Publikováno v:
Journal of Oncology Pharmacy Practice. 27:1891-1895
Introduction The incidence of Ifosfamide-induced encephalopathy (IIE) ranges from 5-30%. Aprepitant and fosaprepitant may increase the risk of IIE; however, data is limited. The objective of this study was to characterize the incidence of IIE in pati
Autor:
Sarah K Cimino, Cathy Eng
Publikováno v:
Journal of Experimental Pharmacology. 12:475-485
Colorectal cancer is one of the top causes of cancer and cancer-related deaths worldwide. The prognosis of metastatic colorectal cancer is poor and treatment options are limited. Many patients will run out of treatment options before they become medi
Autor:
Sarah K Cimino, Hualy Li
Publikováno v:
Journal of Oncology Pharmacy Practice. 26:187-192
PurposeDrug shortages have become a constant challenge in patient care over the past two decades. In 2018, there was a shortage of etoposide injection in the United States. The purpose of this study was to analyze the impact of the etoposide injectio
Publikováno v:
Oncologist
Immune checkpoint inhibitors (ICIs) benefit rare subsets of gastrointestinal (GI) cancer patients. Significant interest exists to identify predictive biomarkers which may increase the applicability of ICI therapy for these patients. Programmed-death